Navigation Links
Positive results for airway bypass
Date:10/9/2007

Mountain View, CA, October 9, 2007 - Broncus Technologies, Inc., a medical device company investigating the airway bypass procedure for the treatment of emphysema, today announced that the results of its open-label Exhale Drug-Eluting Stent feasibility study have been published in the October issue of the Journal of Thoracic and Cardiovascular Surgery. Positive results include a statistically significant reduction in the amount of air trapped in the lungs and an improvement in breathing for patients at six months after the airway bypass procedure.

Airway bypass is a catheter-based bronchoscopic procedure designed to reduce lung hyperinflation and improve breathlessness (the clinical hallmarks of emphysema/COPD) by making new pathways for trapped air to exit the lungs. During the minimally invasive procedure, new openings are created in the airway wall connecting the damaged lung tissue to the natural airway. These pathways are supported and kept open by Exhale Drug-Eluting Stents. The hope is to improve quality of life by relieving severe symptoms including shortness of breath and hyperinflation of the chest.

Emphysema, a component of COPD, is a chronic, progressive, and irreversible lung disease characterized by the destruction of lung tissue. The loss of the lungs' natural elasticity and the collapse of airways in the lung combine to make exhalation ineffective, leaving emphysema sufferers with hyperinflation because they are unable to get air out of their lungs. Breathing becomes inefficient and patients have to work very hard just to breathe making normal activities, like walking, eating or even bathing, difficult. Treatment options for most patients with emphysema are currently limited and generally result in anguished patients and frustrated physicians.

The prospectively-defined primary endpoint of this feasibility study was a reduction in residual volume (RV, the amount of air remaining in the lungs after full exhalation) at 6 months. The goal was for a 300mL reduction in RV. Overall the trial surpassed that goal with a 400mL improvement in RV over baseline at 6 months (p=0.04). Patients also showed a statistically significant improvement in the modified Medical Research Council Dyspnea Scale (mMRC), a breathlessness test, of -0.5 points (p= 0.025). Retrospective analysis revealed that patients with the most severe hyperinflation of their lungs (as determined by a residual volume to total lung capacity ratio above the median) derived the greatest benefit from airway bypass. At 6 months after the procedure, these patients showed a mean improvement in RV of 870mL (p=0.022).

The management of emphysema poses a difficult challenge for the medical community as the disease progressively deprives patients of their ability to perform daily activities. These findings are encouraging because there are so few options for the millions patients who suffer from this disease, states Paulo F.G. Cardoso, M.D., Ph.D, Division of Thoracic Surgery, Santa Casa de Porto Alegre-Pavilhao Pereira Filho Hospital, Brazil and lead author of the paper. These results reveal significant improvements in pulmonary function and reduction in breathing difficulties out to six months and indicate that airway bypass is a potentially viable therapeutic option for patients with marked severe pulmonary destruction, whose only current option may be to wait for a lung transplant.

The data from this study are very exciting, as they help build the case that airway bypass might reduce hyperinflation and have long-term benefit, states Cary Cole, CEO of Broncus. We hope to continue this success with the current, pivotal EASE Trial, our largest clinical study to date.


'/>"/>

Contact: Meghan Oreste
moreste@comcast.net
617-823-1441
Broncus Technologies
Source:Eurekalert

Related biology news :

1. Neurologix announces positive results of gene therapy clinical trial in Parkinsons disease
2. Insight into the processes of positive and negative learners
3. HIV-infected adults in Botswana respond positively to ARV therapy public treatment program
4. Malaria treatment efficacy compromised in certain HIV-positive patients
5. To slow AIDS in Russia, treat HIV-positive addicts, Stanford study says
6. Gene vaccine for Alzheimers disease shows promising results
7. Roche clinical trial registry and results database launched
8. Diabetic nerve therapy shows striking results
9. Results of worlds first gene therapy trial for arthritis show approach safe, feasible
10. New results validating Pall prion reduction filter disclosed at ISBT Congress
11. Tramiprosate (Alzhemed? preclinical results published in Neurobiology of Aging
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/2/2016)... 2, 2016 Checkpoint Inhibitors for Cancer ... Are you interested in the future of ... checkpoint inhibitors. Visiongain,s report gives those predictions to ... national level. Avoid falling behind in data ... and revenues those emerging cancer therapies can achieve. ...
(Date:2/1/2016)... NEW YORK , Feb. 1, 2016  Today, ... Heart Association (AHA) announced plans to develop a first ... cognitive computing power of IBM Watson. In the first ... disease, AHA, IBM (NYSE: IBM ), and Welltok ... metrics and health assessments with cognitive analytics, delivered on ...
(Date:1/25/2016)...  Glencoe Software, the world-leading supplier of image data ... provide the data management solution OMERO Plus for the ... Photo - http://photos.prnewswire.com/prnh/20160125/325328LOGO ... Phenotypic analysis measures the characteristics and behavior of ... states such as health and disease, the presence or ...
Breaking Biology News(10 mins):
(Date:2/11/2016)... ... February 11, 2016 , ... ... has announced a new agreement with Bankok,Thailand-based Global Stem Cells Network (GSCN) to ... in 15 Latin American countries, including Mexico, Costa Rica, Dominican Republic, Colombia, Argentina, ...
(Date:2/10/2016)... , February 10, 2016 Early-career researchers ... , Peru , Uganda and ... life-enhancing work in health and nutrition   Indonesia ... Uganda and Yemen are being ... and epidemiology. They are also celebrated for mentoring young women scientists who ...
(Date:2/10/2016)... ASAE is introducing a hybrid membership model which will ... of joining or renewing through an organizational purchasing model. ... every employee in any size association or AMC office ... member benefits.   John H. Graham, IV ... allow organizations of any size and their employees to ...
(Date:2/10/2016)... 2016  Allergan plc (NYSE: AGN ) a ... Saunders , Allergan,s CEO and President, will be featured ... at the RBC Capital Markets Healthcare Conference on Tuesday, ... New York Palace Hotel in New York, ... and can be accessed on Allergan,s Investor Relations web ...
Breaking Biology Technology: